Rituximab in the treatment of inflammatory myopathies: a review

被引：83

作者：

Fasano, Serena ^{[1
]}

Gordon, Patrick ^{[2
]}

Hajji, Raouf ^{[3
]}

Loyo, Esthela ^{[4
]}

Isenberg, David A. ^{[5
]}

机构：

[1] Univ Naples 2, Dept Clin & Expt Med, Rheumatol Unit, Naples, Italy

[2] Kings Coll Hosp London, Ctr Rheumatol, Dept Med, London, England

[3] Sidi Bouzid Hosp, Fac Sousse, Dept Internal Med, Ibn Aljazzar Med, Sidi Bouzid, Tunisia

[4] Serv Reumatol Inmunol Clin HRUJMCB, Jefe Serv, Santiago, Dominican Rep

[5] UCL, Dept Med, Ctr Rheumatol, London, England

来源：

RHEUMATOLOGY | 2017年 / 56卷 / 01期

关键词：

inflammatory myopathies; dermatomyositis; polymyositis; anti-synthetase syndrome; rituximab; INTERSTITIAL LUNG-DISEASE; ANTI-SYNTHETASE SYNDROME; CELL DEPLETION THERAPY; JUVENILE DERMATOMYOSITIS; REFRACTORY POLYMYOSITIS; RESPIRATORY-FAILURE; MYOSITIS; EFFICACY; PATIENT; ADULT;

D O I：

10.1093/rheumatology/kew146

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Several uncontrolled studies have encouraged the use of rituximab (RTX) in patients with myositis. Unfortunately, the first placebo-phase trial to assess the efficacy of RTX in refractory myositis did not show a significant difference between the two treatment groups, and doubts have been expressed about its study design. In this review we present an up-to-date overview of the reported experiences of RTX therapy in myositis. A PubMed search was performed to find all the available cases of refractory myositis patients treated with RTX up to July 2015. The following terms were assessed: inflammatory myopathies OR anti-synthetase syndrome OR polymyositis OR dermatomyositis AND RTX. A total of 48 studies were included. We identified 458 patients with myositis treated with RTX. We found a rate of response to RTX of 78.3%. RTX can play a role in the management of patients with myositis, at least in those with positive myositis-specific autoantibodies.

引用

页码：26 / 36

页数：11

共 50 条

[41] Diagnosis and treatment of the idiopathic inflammatory myopathies
Gazeley, David J.
Cronin, Mary E.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2011, 3 (06) : 315 - 324
[42] Treatment and investigation of idiopathic inflammatory myopathies
Lundberg, I
Chung, YL
RHEUMATOLOGY, 2000, 39 (01) : 7 - 17
[43] Update on the treatment of idiopathic inflammatory myopathies
Vencovsky, J.
WIENER KLINISCHE WOCHENSCHRIFT, 2014, 126
[44] Cyclosporin a treatment of idiopathic inflammatory myopathies
Ponyi, A
Constantin, T
Dankó, K
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 304 - 304
[45] Pathogenesis, classification and treatment of inflammatory myopathies
Mei Zong
Ingrid E. Lundberg
Nature Reviews Rheumatology, 2011, 7 : 297 - 306
[46] Evaluation and treatment of the idiopathic inflammatory myopathies
Amato, AA
Barohn, RJ
NEUROLOGIST, 2000, 6 (05) : 267 - 287
[47] Idiopathic inflammatory myopathies: A treatment update
Chester V. Oddis
Current Rheumatology Reports, 2003, 5 (6) : 431 - 436
[48] DIAGNOSIS AND TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES
Carolina Costi, Ana
Marcos, Josefina
Pablo Salas, Adrian
Pena, Claudia E.
Arturi, Valeria
Sansinanea, Pierina
Alejandra Pera, Mariana
Aguila Maldonado, Rodrigo
Testi, Adriana
Vulcano, Ariel E.
Argentina Garcia, Mercedes
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2016, 22 (03) : 156 - 156
[49] RITUXIMAB IN THE TREATMENT OF IDIOPATHIC INFLAMMATORY MYOPATHIES WITH INTERSTITIAL LUNG DISEASE, LONG-TERM FOLLOW-UP
Khelkovskaya-Sergeeva, Anna
Garzanova, Ludmila
Ananyeva, Lidia P.
Koneva, Olga
Desinova, Oxana
Ovsyannikova, Olga
Starovoytova, Mayya
Shay-Akhmetova, R.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023, 41 (02) : 497 - 497
[50] Comparison of rituximab efficacy in treatment-naive and refractory inflammatory myopathies: experiences from a tertiary care centre
Manwatkar, Abhilasha
Naresh, Kancha
Mathew, John
Nair, Aditya V.
Goel, Ruchika
Yadav, Bijesh
Prakash, John Antony Jude
Das, John Kumar
Sivadasan, Ajith
RHEUMATOLOGY, 2024,

← 1 2 3 4 5 →